Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD)

被引:10
|
作者
Kragh Petersen, Sine [1 ]
Bilkei-Gorzo, Orsolya [1 ]
Govaere, Olivier [2 ]
Hartlova, Anetta [1 ]
机构
[1] Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden
[2] Newcastle Univ, Translat & Clin Res Inst, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England
关键词
lipid metabolism; macrophages; NAFLD; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; KUPFFER CELLS; ADIPOSE-TISSUE; HEPATIC STEATOSIS; HEPATOCELLULAR-CARCINOMA; INSULIN-RESISTANCE; INFILTRATION; PROLIFERATION; INFLAMMATION;
D O I
10.1111/sji.12971
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
With an increase in sedentary lifestyle and dietary over nutrition, obesity has become one of the major public health problems worldwide and is a prevalent predisposing risk factor to non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease in Western developed countries. NAFLD represents a series of diseased states ranging from non-alcoholic fatty liver (NAFL) to steatohepatitis (NASH), which can lead to fibrosis and eventually to cirrhosis and hepatocellular carcinoma. Currently, the only effective treatment to cure end-stage liver disease is liver transplantation. Macrophages have been reported to play a crucial role in the progression of NAFLD, thereby are a potential target for therapy. In this review, we discuss the current knowledge on the role of macrophages and inflammatory signalling pathways associated with obesity and chronic liver inflammation, and their contribution to NAFLD development and progression.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Obesity and non-alcoholic fatty liver disease
    不详
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 40 (05): : 686 - 687
  • [22] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
    Bugianesi, E
    Marzocchi, R
    Villanova, N
    Marchesini, G
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1105 - 1116
  • [23] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Jürgen Kurt Rockstroh
    [J]. Current HIV/AIDS Reports, 2017, 14 : 47 - 53
  • [24] Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae
    Karlas, Thomas
    Wiegand, Johannes
    Berg, Thomas
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 27 (02) : 195 - 208
  • [25] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Rockstroh, Juergen Kurt
    [J]. CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
  • [26] How Common Is Non-Alcoholic Fatty Liver Disease (NAFLD) Among Children With Obesity?
    Blanck, Heidi
    Goodman, Alyson
    Porter, Renee
    Kraus, Emily
    Belay, Brook
    Kompaniyets, Lyudmyla
    Vos, Miriam
    King, Raymond
    [J]. OBESITY, 2020, 28 : 22 - 23
  • [27] A lipidomic analysis of non-alcoholic fatty liver disease (NAFLD)
    Puri, P.
    Baillie, R. A.
    Wiest, M.
    Mirshahi, F.
    Sanyal, A. J.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S260 - S261
  • [28] Non-alcoholic Fatty Liver Disease Diagnosis and Therapy of NAFLD
    不详
    [J]. GASTROENTEROLOGE, 2021, 16 (05): : 386 - 386
  • [29] Diagnosis and management of non-alcoholic fatty liver disease (NAFLD)
    Byrne, C. D.
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2018, 94 : A2 - A2
  • [30] Antiepileptic drugs and non-alcoholic fatty liver disease (NAFLD)
    Waldmann, M
    Sturm, W
    Naser, A
    Unterberger, I
    Trinka, E
    Bauer, G
    Lechleitner, M
    Luef, G
    [J]. EPILEPSIA, 2004, 45 : 161 - 162